Liminatus Pharma, Inc. (LIMN)
NASDAQ:LIMN
Total Valuation
Liminatus Pharma has a market cap or net worth of $8.26M. The enterprise value is $6.04M.
Market Cap$8.26M
Enterprise Value$6.04M
Share Statistics
Liminatus Pharma has 44,877,632 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,877,632
Owned by Insiders―
Owned by Institutions0.03%
Financial Efficiency
Liminatus Pharma’s return on equity (ROE) is 1.04 and return on invested capital (ROIC) is 35.57%.
Return on Equity (ROE)1.04
Return on Assets (ROA)-19.90
Return on Invested Capital (ROIC)35.57%
Return on Capital Employed (ROCE)0.30
Revenue Per Employee0.00
Profits Per Employee-3.40M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Liminatus Pharma is ―. Liminatus Pharma’s PEG ratio is -0.19.
PE Ratio―
PS Ratio0.00
PB Ratio-1.48
Price to Fair Value-1.48
Price to FCF-1.45
Price to Operating Cash Flow-0.44
PEG Ratio-0.19
Income Statement
In the last 12 months, Liminatus Pharma had revenue of 0.00 and earned -10.21M in profits. Earnings per share was -0.43.
Revenue0.00
Gross Profit0.00
Operating Income-2.97M
Pretax Income-10.21M
Net Income-10.21M
EBITDA-9.99M
Earnings Per Share (EPS)-0.43
Cash Flow
In the last 12 months, operating cash flow was -9.96M and capital expenditures -13.11K, giving a free cash flow of -9.98M billion.
Operating Cash Flow-9.96M
Free Cash Flow-9.98M
Free Cash Flow per Share-0.22
Dividends & Yields
Liminatus Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change-97.96%
50-Day Moving Average0.43
200-Day Moving Average2.44
Relative Strength Index (RSI)36.94
Average Volume (3m)1.54M
Important Dates
Liminatus Pharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Liminatus Pharma as a current ratio of 0.05, with Debt / Equity ratio of -14.70%
Current Ratio0.05
Quick Ratio0.05
Debt to Market Cap0.10
Net Debt to EBITDA-0.11
Interest Coverage Ratio-13.75
Taxes
In the past 12 months, Liminatus Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Liminatus Pharma EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -1.56.
EV to Sales0.00
EV to EBITDA-1.56
EV to Free Cash Flow-1.56
EV to Operating Cash Flow-1.57
Balance Sheet
Liminatus Pharma has $337.65K in cash and marketable securities with $1.44M in debt, giving a net cash position of -$1.10M billion.
Cash & Marketable Securities$337.65K
Total Debt$1.44M
Net Cash-$1.10M
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Liminatus Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―